BioLine Rx Ltd (BLRX)

1.11
0.01 0.91
NASDAQ : Health Care
Prev Close 1.10
Open 1.10
Day Low/High 1.07 / 1.12
52 Wk Low/High 0.71 / 2.25
Volume 142.40K
Avg Volume 587.80K
Exchange NASDAQ
Shares Outstanding 104.10M
Market Cap 114.51M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx To Report Second Quarter 2015 Results On August 20, 2015

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

BioLineRx (BLRX) shares are down by almost 20% after the company confirmed weak results from its placebo-controlled heart disease treatment tests.

BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)

BioLineRx Announces Top-Line Results From Bellerophon's PRESERVATION I Clinical Trial For Bioabsorbable Cardiac Matrix (BL-1040)

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its partner, Bellerophon,...

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation

Bioline RX (BLRX) shares are rising as it presents in the Celiac Disease Symposium in Prague this week as well as coverage initiation by analysts at JPMorgan.

BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium

BioLineRx To Present Successful Results Of Phase 1/2 Study For Novel Celiac Treatment At International Celiac Disease Symposium

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will present positive...

BioLineRx To Present At The JMP Securities Life Sciences Conference In New York

BioLineRx To Present At The JMP Securities Life Sciences Conference In New York

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Financial and...

Research Underlying BioLineRx's Treatment Of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award

Research Underlying BioLineRx's Treatment Of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for...

BioLineRx Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions

BioLineRx Announces Peer-Reviewed Publication Of Phase 1/2 Trial Results For Novel Treatment For Non-Surgical Removal Of Skin Lesions

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the publication of positive...

BioLineRx To Present Positive Safety And Efficacy Clinical Data For Novel Stem Cell Mobilization Treatment At The European Hematology Annual Congress

BioLineRx To Present Positive Safety And Efficacy Clinical Data For Novel Stem Cell Mobilization Treatment At The European Hematology Annual Congress

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that positive safety and...

BioLineRx Reports First Quarter 2015 Financial Results

BioLineRx Reports First Quarter 2015 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the...

BioLineRx To Report First Quarter 2015 Results On May 18, 2015

BioLineRx To Report First Quarter 2015 Results On May 18, 2015

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...

BioLineRx Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia

BioLineRx Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful completion of the dose...

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment

BioLineRx Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today successful top-line results...

3 Stocks Under $10 Making Big Moves Higher

3 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

BioLineRx Reports Year End 2014 Financial Results

BioLineRx Reports Year End 2014 Financial Results

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the...

BioLineRx To Report Fourth Quarter And Year End 2014 Results On March 23, 2015

BioLineRx To Report Fourth Quarter And Year End 2014 Results On March 23, 2015

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its...

BioLineRx Closes $28.75 Million Underwritten Public Offering Of Its American Depositary Shares

BioLineRx Closes $28.75 Million Underwritten Public Offering Of Its American Depositary Shares

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has closed its...

BioLineRx's Treatment For Type 1 Diabetes Effective In Preclinical Trials

BioLineRx's Treatment For Type 1 Diabetes Effective In Preclinical Trials

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results...

BioLineRx To Present At The Annual Roth Conference In California

BioLineRx To Present At The Annual Roth Conference In California

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Prices $25 Million Underwritten Public Offering Of Its American Depositary Shares

BioLineRx Prices $25 Million Underwritten Public Offering Of Its American Depositary Shares

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has priced an...

BioLineRx Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory...

BioLineRx To Present At 2015 BIO CEO & Investor Conference In New York On February 10

BioLineRx To Present At 2015 BIO CEO & Investor Conference In New York On February 10

BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction

BioLineRx Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that patient enrollment has been...

BioLineRx Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment

BioLineRx Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has completed the dose...

BioLineRx To Present At Biotech Showcase 2015 Conference In San Francisco

BioLineRx To Present At Biotech Showcase 2015 Conference In San Francisco

BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer,...

BioLineRx Out-Licenses Novel Skin Lesion Treatment To Omega Pharma

BioLineRx Out-Licenses Novel Skin Lesion Treatment To Omega Pharma

BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has entered into an...

BioLineRx And Major Global Pharmaceutical Company Form Strategic Collaboration For Screening And Development Of Novel Drug Candidates

BioLineRx And Major Global Pharmaceutical Company Form Strategic Collaboration For Screening And Development Of Novel Drug Candidates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today announced that it has entered into a...

BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform

BioLineRx Presents Multi-Year Clinical Development Plan For Its BL-8040 Hematological Cancer Therapeutic Platform

During an investor and analyst meeting hosted today in New York, BioLineRx Ltd.

BioLineRx Reports Positive Data From Ongoing Phase 2a Study For AML Treatment At ASH Conference

BioLineRx Reports Positive Data From Ongoing Phase 2a Study For AML Treatment At ASH Conference

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that data from the...